Yersinia pseudotuberculosis Infectious Disease — Comprehensive Disease-Characteristics Report

MONDO ID: MONDO:0007024 | Category: Infectious Disease | Causative agent: Yersinia pseudotuberculosis (NCBI:txid633)

Evidence base: Aggregated disease-level literature (PubMed reviews, primary microbiology/immunology studies, human clinical case series, model-organism experiments). No individual patient/EHR data or omics files were provided; all statements are literature-derived and cited by PMID.

Summary

Yersinia pseudotuberculosis infectious disease is an acute, zoonotic, foodborne enteric infection caused by the cold-tolerant (psychrotrophic) Gram-negative coccobacillus Y. pseudotuberculosis. The pathogen is acquired fecal-orally from contaminated water, produce, or meat, and it uniquely proliferates under refrigeration, which shapes both its epidemiology and its prevention. The disease shows a striking geographic dichotomy: in Europe and most of the world it manifests as a self-limiting gastroenteritis or, in children, as fever with mesenteric lymphadenitis and terminal ileitis that mimics acute appendicitis ("pseudoappendicitis"). In Russia and Japan, by contrast, epidemic strains cause a severe systemic inflammatory disease historically called Far East scarlet-like fever (FESLF), characterized by scarlatiniform rash, arthralgia, and toxic-shock-like features.

The pathophysiology is bacterial-effector driven, not host-genetic. The organism enters through M cells over the Peyer's patches using the chromosomal adhesin invasin (a high-affinity β1-integrin ligand), replicates in the intestine, and then disseminates to mesenteric lymph nodes, liver, and spleen. A temperature-regulated type III secretion system (T3SS) encoded on the pYV virulence plasmid — switched on at 37 °C by the master regulator LcrF — injects Yop effector proteins that paralyze phagocytes and disable innate immune signaling (NF-κB, MAPK, IRF3). The severe FESLF phenotype is additionally determined by strain plasmid/superantigen content: the pVM82 plasmid and the superantigen YPMa (Y. pseudotuberculosis-derived mitogen A), which overstimulates CD4⁺ Vβ3/Vβ7/Vβ8 T cells to release a TNF-α/IFN-γ cytokine storm.

The disease is generally self-limiting with an excellent prognosis, and the organism is broadly antibiotic-susceptible (fluoroquinolones, third-generation cephalosporins, aminoglycosides, tetracyclines). Severe systemic and septicemic disease is concentrated in hosts with iron overload, desferrioxamine therapy, or immunosuppression. Post-infectious immune sequelae — reactive arthritis and erythema nodosum — occur in a minority. Notably, Y. pseudotuberculosis is the recent enteric evolutionary ancestor of Y. pestis (plague). Prevention rests on food and water hygiene; no human vaccine exists. This report synthesizes 12 confirmed findings from 46 reviewed papers across all 15 requested disease-characteristic domains.

1. Disease Information

Overview. Yersinia pseudotuberculosis infectious disease (yersiniosis due to Y. pseudotuberculosis) is an acute enteric zoonosis. Clinically it presents along a spectrum from self-limiting gastroenteritis to pseudoappendicitis (mesenteric adenitis/terminal ileitis) to, in the Far East, a severe systemic scarlet-fever-like illness. It is caused by a Gram-negative, facultatively anaerobic, motile (at ≤30 °C), psychrotrophic member of the family Yersiniaceae.

Key identifiers: - MONDO: MONDO:0007024 - MeSH: Yersinia pseudotuberculosis Infections - ICD-10: A28.2 (Extraintestinal yersiniosis) / A04.8 (other bacterial intestinal infections) - Pathogen taxonomy: NCBI:txid633 (Yersinia pseudotuberculosis) - OMIM/Orphanet: not a Mendelian disorder; no OMIM entry (infectious, not genetic). Orphanet lists Far East scarlet-like fever as a rare condition.

Synonyms / alternative names: Far East scarlet-like fever (FESLF); Izumi fever (historical Japanese name); pseudotuberculosis; Pasteurella pseudotuberculosis infection (historical bacterial name); scarlatinoid fever.

Information source type. The evidence base is aggregated disease-level literature (case series, outbreak investigations, microbiology and animal-model studies, and serosurveys) rather than individual EHR-derived cohorts. Much quantitative sequelae data are extrapolated from the closely related Y. enterocolitica.

The two-faced clinical identity is the anchoring finding (F001):

"Far East scarlet-like fever is caused by Yersinia pseudotubuclosis infection, an organism that typically causes self-limiting gastroenteritis in Europe." — Amphlett 2016, PMID: 26819960

"Geographical heterogeneity exists between virulence factors produced by European and Far Eastern Y pseudotuberculosis strains, implicating superantigen Y pseudotuberculosis-derived mitogen A (YPMa) in the pathogenesis of FESLF." — PMID: 26819960

2. Etiology

Primary cause. The disease is infectious, caused entirely by Y. pseudotuberculosis. There is no genetic (Mendelian) etiology in the human host. Disease severity is governed by pathogen genotype (plasmid and superantigen content) interacting with host iron status and immune competence.

Environmental / exposure risk factors: - Foodborne/waterborne transmission via contaminated refrigerated food, raw vegetables (lettuce, carrots), untreated water, and meat (F012). - Animal contact — broad wildlife and domestic-animal reservoirs (F008). - Age — children are disproportionately affected by the pseudoappendicitis form. - Cold storage — the organism's psychrotrophic growth increases the infectious dose reachable in refrigerated foods.

Host risk factors for severe/systemic disease (F010): - Iron overload (e.g., β-thalassemia, hemochromatosis). - Desferrioxamine (DFO) iron-chelation therapy — DFO acts as a xenosiderophore delivering iron to the bacterium. - Immunosuppression and splenectomy.

"Patients undergoing DFO therapy are at risk for Y. enterocolitica infection which may be localized to mesenteric nodes and tonsils or occur as a generalized form such as septicemia." — Wanachiwanawin 2000, PMID: 11132234

Genetic protective / risk factors: None established in humans. Susceptibility is essentially universal; outcome modulation is by iron availability and immune status rather than host germline variants.

Gene–environment interaction. The key "interaction" is host iron availability × bacterial iron acquisition: excess free iron (from overload or DFO chelation therapy) supports rapid bacterial growth and systemic dissemination, converting a normally contained enteric infection into septicemia.

3. Phenotypes

Phenotype spectrum evidence (F006):

"responsible for scarlatinoid fever, food poisoning, post-infectious complications like erythema nodosum/reactive arthritis as well as pseudoappendicitis in children" — Basharat 2021, PMID: 33321204

Reactive-arthritis frequency (extrapolated from Y. enterocolitica population study, F006):

"Self-reported symptoms consistent with ReA were reported by 12% of yersiniosis patients compared to 5% in a reference group not exposed to yersiniosis." — Rosner 2013, PMID: 23701958

Onset/severity/progression: acute onset; self-limiting in most; systemic FESLF is more severe and correlates with higher anti-YPM titers. Quality of life: acute illness is generally short-lived; the main QoL burden falls on the minority with reactive arthritis (weeks–months of joint pain).

4. Genetic/Molecular Information

This is an infectious disease; there are no human causal genes, pathogenic germline variants, chromosomal abnormalities, or Mendelian inheritance. The "genetics" of the disease are the genetics of the pathogen.

Key bacterial virulence loci: - pYV / pCD1 virulence plasmid (~70 kb): encodes the Ysc T3SS and Yop effectors (YopH, YopE, YopT, YopJ/YopP, YopM, YopO/YpkA) plus the master regulator LcrF (VirF). - Chromosomal inv gene:* invasin, the β1-integrin adhesin for M-cell entry. - ail, yadA (plasmid): adhesion/serum resistance. - YPMa gene (ypmA*): superantigen; hallmark of Far Eastern strains. - pVM82 plasmid (~82 MDa): present only in FESLF-causing strains (F011).

Strain plasmid genotype determines clinical severity (F011):

"effects of pathogenicity of an understudied pVM82 plasmid present only in Y pseudotuberculosis sttains causing clinical-epidemic manifestation of the infections as Far East scarlet-like fever (FESLF)" — Somova 2016, PMID: 30695393

"Variability of damage of innate immunity cells and target-organs caused by various plasmid types of Y pseudotuberculosis by virulence could determine polymorphism of clinical-morphological manifestations of this infection." — PMID: 30695393

Serotypes: ≥21 O-serotypes exist; Y. pestis evolved from serotype O:1b (F005).

5. Environmental Information

Infectious agent (NCBI Taxon): Yersinia pseudotuberculosis, NCBI:txid633.

Environmental/transmission factors: - Cold tolerance (psychrotrophy): enables growth in refrigerated foods (F012).

"Yersinia enterocolitica and Yersinia pseudotuberculosis are important foodborne pathogens that cause infections through contaminated refrigerated food." — Palonen 2010, PMID: 20088683

• Food vehicles: raw vegetables, lettuce, carrots, untreated water, meat.
• Animal reservoirs: pigs, sheep, wild birds, rodents, deer, and many others; food/livestock strains are molecularly indistinguishable from human isolates (F008).

"All human Y. pseudotuberculosis 1/O:1 strains were indistinguishable from pig, sheep or food strains." — Okwori 2009, PMID: 19835774

Lifestyle factors: consumption of raw/undercooked produce and unpasteurized/untreated water; exposure to farm and wild animals.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating event → clinical manifestation)

1.  Ingestion of contaminated refrigerated food/water
        → delivers viable Y. pseudotuberculosis to the small intestine
2.  Chromosomal invasin binds host β1-integrins on M cells (Peyer's patches)
        → results in translocation across the follicle-associated epithelium
3.  Invasin–β1-integrin engagement activates Rac1, MAP kinases, NF-κB
        → drives local chemokine production and bacterial uptake
4.  Bacteria replicate in the intestinal lumen/lamina propria
        → establishes a replicating pool (required for later dissemination)
5.  Host body temperature (37 °C) is sensed by an RNA thermometer + YmoA
        → de-represses the master regulator LcrF
6.  LcrF activates the pYV-encoded Ysc T3SS and yop genes
        → injects Yop effectors into phagocytes on contact
7a. YopH/YopE/YopT/YopO disrupt phagocyte cytoskeleton/Rho GTPases
        → results in resistance to phagocytosis (antiphagocytic defense)
7b. YopJ acetylates/deubiquitinates TAK1 and reduces K63-ubiquitination
    of TRAF3/TRAF6
        → blocks NF-κB, MAPK, and IRF3 signaling
        → suppresses innate cytokine and interferon responses
8.  Surviving extracellular bacteria disseminate to mesenteric lymph
    nodes, liver, spleen
        → mesenteric lymphadenitis / pseudoappendicitis / abscessation

        ┌──────────────── BRANCH: strain genotype ────────────────┐
        │ European strains          │ Far Eastern strains          │
        │ (YPMa-/pVM82-)             │ (YPMa+, pVM82+)              │
        │  → localized, self-limiting│  → superantigen released     │
        │    gastroenteritis /       │                              │
        │    pseudoappendicitis      │                              │
        └────────────────────────────┴──────────────────────────────┘
9.  (Far East) YPMa superantigen cross-links MHC-II to TCR Vβ3/Vβ7/Vβ8
        → massive polyclonal CD4+ T-cell activation
10. Activated T cells release TNF-α and IFN-γ
        → systemic inflammation, rash, renal dysfunction, toxic shock (FESLF)
11. (Post-infectious, in a minority) molecular mimicry / immune complexes
        → reactive arthritis and erythema nodosum weeks after infection

Detail by category

Molecular pathways. Host invasin signaling engages Rac1 → MAPK → NF-κB. Bacterial YopJ targets the NF-κB, MAPK, and IRF3 pathways (F009):

"YopJ inhibited TLR-mediated NF-kappaB and MAP kinase activation, as suggested by previous studies. In addition, induction of the TLR-mediated interferon response was blocked by YopJ, indicating that YopJ also inhibits IRF3 signalling." — Sweet 2007, PMID: 17608743

Cellular processes. Inflammation (GO:0006954), inhibition of phagocytosis (GO:0006909), suppression of innate immune signaling, superantigen-driven T-cell proliferation (GO:0042110).

Protein dysfunction (bacterial effectors as toxins): YopH (tyrosine phosphatase), YopE/YopT (Rho GAP/protease), YopJ (acetyltransferase/deubiquitinase), YopO/YpkA (kinase), YopM (leukocyte-modulating). LcrF is the thermo-activated transcriptional master switch.

Temperature control is the master mechanism (F003):

"two different Y. pseudotuberculosis patient isolates expressing a stabilized thermometer variant were strongly reduced in their ability to disseminate into the Peyer's patches, liver and spleen and have fully lost their lethality" — Böhme 2012, PMID: 22359501

"Ysc-T3SS-mediated Yop secretion leads to global reprogramming of the Yersinia transcriptome with a massive shift of the expression from chromosomal to virulence plasmid-encoded genes" — Meyer 2024, PMID: 39159284

Intestinal entry mechanism (F004):

"Invasin protein is a high-affinity ligand for beta1 integrins and especially important in the early phase of intestinal infection for efficient translocation through the M cells located in the follicle-associated epithelium overlying the Peyer's patches." — Grassl 2003, PMID: 12755365

"Replication of bacteria in the intestine before translocation appeared critical for dissemination" — Barnes 2006, PMID: 16754724

Superantigen mechanism (F002):

"Patients with systemic symptoms such as lymphadenopathy, transient renal dysfunction, and arthritis had significantly higher titers of anti-YPM than patients with gastrointestinal tract symptoms alone." — Abe 1997, PMID: 9109426

"This shock was blocked by the injection of monoclonal antibodies (mAbs) to CD4, TCR Vbeta7 plus Vbeta8, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma)" — Miyoshi-Akiyama 1997, PMID: 9159409

Quantitatively (F002): 20/33 (61%) of acutely infected patients had elevated anti-YPM IgG vs controls (P=0.0001); Vβ3⁺ T cells were significantly increased in the acute phase (P=0.009).

Immune involvement: the disease is a contest between bacterial innate-immune evasion (Yop-mediated) and, in FESLF, pathological adaptive over-activation (superantigen-mediated). Cell types (CL): M cells, macrophages/neutrophils (CL:0000235, CL:0000775), CD4⁺ T cells (CL:0000624), dendritic cells (CL:0000451). GO biological processes: GO:0006909 (phagocytosis), GO:0042110 (T-cell activation), GO:0006954 (inflammatory response), GO:0043123 (positive regulation of NF-κB), GO:0009266 (response to temperature stimulus).

7. Anatomical Structures Affected

Organ level (primary): - Terminal ileum and cecum (UBERON:0002116; UBERON:0001153) - Mesenteric lymph nodes (UBERON:0002509) - Peyer's patches / gut-associated lymphoid tissue (UBERON:0003454)

Secondary organ involvement (dissemination/complications): - Liver (UBERON:0002107) and spleen (UBERON:0002106) — hepatosplenic abscessation - Skin (UBERON:0002097) — rash, erythema nodosum - Joints (UBERON:0000467 articular system) — reactive arthritis - Kidney (UBERON:0002113) — transient renal dysfunction in FESLF - Rarely muscle (myositis) and heart (myocarditis)

Body systems: digestive, lymphatic/immune, integumentary, musculoskeletal, and (in systemic disease) renal.

Tissue/cell level: intestinal follicle-associated epithelium (M cells), lymphoid tissue, professional phagocytes (macrophages, neutrophils), CD4⁺ T lymphocytes.

Subcellular (GO Cellular Component): host plasma membrane (GO:0005886, invasin–integrin contact and T3SS translocon), cytosol (GO:0005829, Yop effector site of action), and the bacterial T3SS injectisome.

Localization/lateralization: RLQ abdominal involvement (ileocecal) is characteristic; disease is systemic rather than lateralized.

8. Temporal Development

• Onset: acute to subacute after a short incubation (typically days). Predominantly affects children and young adults for the pseudoappendicitis form.
• Course: most cases are self-limiting over 1–3 weeks. FESLF is a more severe acute systemic illness.
• Stages: (1) intestinal colonization/replication → (2) lymphatic dissemination (mesenteric adenitis) → (3) possible systemic spread (hepatosplenic; FESLF) → (4) post-infectious immune sequelae (reactive arthritis, erythema nodosum) weeks later.
• Progression rate: generally self-limited; severe/septicemic progression is concentrated in iron-overloaded/immunosuppressed hosts.
• Remission: spontaneous in most; antibiotic-responsive in systemic disease.
• Critical period: the 37 °C temperature shift on host entry is the decisive window that activates the T3SS virulence program (F003).

9. Inheritance and Population

Inheritance: Not applicable — infectious, non-heritable. No inheritance pattern, penetrance, expressivity, anticipation, founder effects, or carrier frequency.

Epidemiology: - Sporadic worldwide; epidemic FESLF clusters in the Russian Far East and Japan (F011).

"Pseudotuberculosis in humans until the 1950s was found in different countries of the world as a rare sporadic disease that occurred in the form of acute appendicitis and mesenteric lymphadenitis." — Somova 2020, PMID: 32498317

• Geographic distribution: European strains cause mild disease; Far Eastern strains (YPMa⁺, pVM82⁺) cause severe systemic disease — a genotype-driven geographic virulence gradient (F001).
• Age distribution: skewed toward children/young adults for pseudoappendicitis.
• Sex ratio: no strong, well-established skew for the enteric form.
• Serotype geography: ≥21 O-serotypes; distinct serotype/plasmid profiles by region.

10. Diagnostics

Two-tier diagnostic strategy (F007):

Acute disease — direct detection: - Stool culture (cold enrichment exploits psychrotrophy), tissue/mesenteric node culture. - PCR for species/virulence genes (inv, ypmA, O-antigen gene clusters). - Imaging (CT/ultrasound): mesenteric lymphadenopathy, terminal ileitis — helps distinguish from surgical appendicitis.

Post-infectious / chronic disease — serology:

"Whereas early infections can be diagnosed by direct detection of bacteria, chronic infections can only be identified by serological tests." — Wielkoszynski 2018, PMID: 30238343

Species-discriminating serology uses recombinant antigens (F007):

"discrimination between the two types of infection is based on two recombinant bacterial proteins, MyfA and PsaA (specific for Y. enterocolitica and Y. pseudotuberculosis, respectively)" — PMID: 30238343

O-genotyping by multiplex PCR of O-antigen gene clusters replaces classical serotyping and distinguishes Y. pseudotuberculosis from Y. pestis (Bogdanovich 2003, PMID: 14605146).

Differential diagnosis: acute appendicitis, Y. enterocolitica infection, Crohn's terminal ileitis, Kawasaki disease (notably — several case reports link Y. pseudotuberculosis to KD-like presentations, e.g., PMID: 9202805), streptococcal scarlet fever, and other causes of reactive arthritis/erythema nodosum.

Omics diagnostics: not routine; PCR-based genotyping is the molecular standard.

11. Outcome / Prognosis

• Overall prognosis: excellent. Most infections are self-limiting with full recovery.
• Mortality: low in immunocompetent hosts; significant risk of fatal septicemia in iron-overloaded, DFO-treated, splenectomized, or immunosuppressed patients (F010).
• Morbidity: driven by post-infectious reactive arthritis (~12% of yersiniosis, weeks–months of disability) and erythema nodosum (~3%) (F006); rare myositis/myocarditis.
• Recovery: high; antibiotics accelerate resolution of systemic disease.
• Prognostic factors: host iron status, immune competence, and infecting-strain genotype (YPMa/pVM82 → severe FESLF). High anti-YPM titers correlate with systemic rather than purely GI disease (a prognostic serologic marker) (F002).

12. Treatment

Pharmacotherapy. The organism is broadly antibiotic-susceptible (F005):

"None of the 58 Y. pseudotuber-culosis isolates was resistant to any tested antimicrobial." — Kim 2017, PMID: 28222842

• Mild self-limiting gastroenteritis typically needs only supportive care (rehydration).
• Systemic/FESLF/septicemia and high-risk hosts warrant antibiotics.
• Caveat — antibiotic tolerance: T3SS-induced growth arrest can reduce susceptibility to gentamicin and doxycycline in subpopulations within host tissues (PMID: 40623067; PMID: 32753491).

Supportive care: hydration; NSAIDs for reactive arthritis/erythema nodosum. Surgical: occasionally unnecessary appendectomy is performed before diagnosis is clarified. No gene, cell, or RNA-based therapies are relevant.

13. Prevention

No licensed human vaccine exists. Prevention is centered on interrupting foodborne transmission (F012):

• Primary prevention (food/water hygiene): wash raw produce; treat/boil water; safe meat handling; recognize that refrigeration does not stop this psychrotroph, so cold storage is not protective.
• Secondary prevention: early culture-based diagnosis to avoid unnecessary appendectomy and to guide antibiotics in high-risk hosts.
• Tertiary prevention: prompt antibiotics and iron-management vigilance in β-thalassemia/hemochromatosis/DFO patients to prevent septicemia (F010).
• Public health / veterinary: reservoir control in livestock and food-processing hygiene; molecular surveillance links animal/food strains to human cases (F008, PMID: 19835774).

14. Other Species / Natural Disease

Zoonotic pathogen with broad reservoirs (F008):

"Yersinia pseudotuberculosis and Yersinia enterocolitica are ubiquitous pathogens with wildlife and domestic animal reservoirs." — Walker 2018, PMID: 30360909

• Natural disease in animals: systemic Y. pseudotuberculosis O:1 causing multi-organ abscessation and osteomyelitis in a ring-tailed lemur (Lemur catta); outbreaks in zoological/research primate colonies (enteritis, mesenteric lymphadenitis, organ abscessation) (Walker 2018, PMID: 30360909).
• Livestock: serotype III causes "winter scours" diarrhea outbreaks in weaned Merino sheep, seasonally in winter (Stanger 2018, PMID: 29691860).
• Wildlife surveillance: beech marten and Alpine ibex identified as reservoirs, carrying mobilizable virulence plasmids (Carella 2022, PMID: 35892105).
• Species affected (NCBI Taxonomy): pigs (txid9823), sheep (txid9940), primates including Lemur catta (txid9447), deer, rodents, birds, humans (txid9606).

Comparative / evolutionary biology (F005): Y. pseudotuberculosis is the recent enteric ancestor of Y. pestis:

"Conventional microbiology, bacterial population genetics, and genome sequence data, all suggest that Y pestis is a recently evolved clone of the enteric pathogen Yersinia pseudotuberculosis." — Prentice & Rahalison 2007, PMID: 17416264

Zoonotic transmission: fecal–oral via contaminated food/water; strain identity between human, pig, sheep, and food isolates confirms cross-species/food-chain transmission (F008).

15. Model Organisms

• Mouse (oral infection model) — the principal model. Recapitulates M-cell/Peyer's-patch entry, intestinal replication, and hepatosplenic dissemination; used to prove the temperature/T3SS and superantigen mechanisms.
• Böhme 2012 (PMID: 22359501): oral mouse infection demonstrated that a locked thermometer variant loses dissemination and lethality.
• Barnes 2006 (PMID: 16754724): oral mouse model showed intestinal replication precedes dissemination.
• Miyoshi-Akiyama 1997 (PMID: 9159409): murine YPM model established MHC-II-dependent Vβ7/Vβ8 expansion and TNF-α/IFN-γ-mediated lethal shock.
• Galleria mellonella (invertebrate infection model) — used for virulence/regulation studies (e.g., Fis regulator, PMID: 41880349).
• Cell-culture / in vitro — epithelial cell invasion assays (invasin–β1-integrin), phagocyte intoxication assays (YopE/YopB-D), RNAi screens for host T3SS cofactors (e.g., CCR5, PMID: 25691588).
• Phenotype recapitulation: the mouse oral model reproduces the enteric-to-systemic axis very well; it does not fully reproduce human FESLF because human-specific superantigen (YPMa) effects and the pVM82-linked epidemic phenotype are strain- and host-context dependent.

Mechanistic Model / Interpretation

The disease is best understood as a two-stage, genotype-branched infection:

                       Y. pseudotuberculosis (ingested, cold-tolerant)
                                        |
                          invasin -> β1-integrin -> M cells
                                        |
                        intestinal replication (Peyer's patches)
                                        |
       37°C -> RNA thermometer/YmoA -> LcrF -> Ysc T3SS -> Yop effectors
              (YopH/E/T/O paralyze phagocytes; YopJ silences NF-κB/MAPK/IRF3)
                                        |
                    dissemination -> mesenteric nodes, liver, spleen
                                        |
        +-------------------------------+-------------------------------+
   European genotype                                        Far Eastern genotype
   (YPMa-, pVM82-)                                          (YPMa+, pVM82+)
        |                                                            |
  self-limiting gastroenteritis /                     YPMa superantigen ->
  pseudoappendicitis                                  Vβ3/7/8 CD4+ T-cell storm ->
        |                                             TNF-α/IFN-γ -> FESLF
        +---------------- post-infectious immune sequelae -----------+
                     (reactive arthritis ~12%, erythema nodosum ~3%)

  Host modifier: iron overload / DFO / immunosuppression -> septicemia

Upstream vs downstream: temperature sensing → LcrF → T3SS is the upstream master switch; Yop-mediated immune paralysis and (in FESLF) superantigen T-cell activation are downstream effectors; post-infectious arthritis/erythema nodosum are terminal immune sequelae. The pathogen genotype (plasmid/superantigen content) is the single strongest determinant of whether the outcome is mild or severe.

Evidence Base

Limitations and Knowledge Gaps

1. Quantitative human epidemiology is sparse. Precise incidence/prevalence (per 100,000) for Y. pseudotuberculosis specifically are not well established; many sequelae frequencies (reactive arthritis ~12%, erythema nodosum ~3%) are extrapolated from Y. enterocolitica population studies rather than measured for Y. pseudotuberculosis directly.
2. FESLF molecular detail is understudied. The pVM82 plasmid's gene content and the precise mechanistic link between pVM82 and the FESLF phenotype remain incompletely defined; YPMa's role is strongly implicated but the causal chain to renal dysfunction is partly inferred.
3. No human host-genetic risk data. Because this is infectious, no GWAS/germline susceptibility data exist; iron availability is the dominant, well-supported host modifier.
4. Kawasaki-disease association is unresolved. Several case reports link Y. pseudotuberculosis to KD-like illness, but causation vs. coincidence/molecular mimicry is not established.
5. Antibiotic tolerance in tissue (T3SS-induced growth arrest reducing aminoglycoside/tetracycline killing) is demonstrated in mouse models but its clinical treatment-failure significance in humans is unquantified.
6. No original data analysis was performed in this investigation; findings are literature-derived syntheses, so confidence rests on the quality of the cited primary studies.

Proposed Follow-up Experiments / Actions

1. Quantify Y. pseudotuberculosis-specific sequelae in a prospective human cohort (rather than extrapolating from Y. enterocolitica), stratified by infecting serotype and YPMa/pVM82 status.
2. Complete pVM82 functional genomics: sequence and mutate pVM82 loci to define which genes are necessary/sufficient for FESLF-associated renal and vascular pathology.
3. Structure-guided anti-superantigen therapeutics: build on the YPM point-mutant work (PMID: 10087177) to develop TCR-Vβ-blocking or attenuated-toxoid immunotherapeutics for severe FESLF.
4. Clinical tolerance study: test whether T3SS-induced antibiotic tolerance drives relapse in systemic human disease and whether combination regimens or T3SS inhibitors improve clearance.
5. Iron-management guideline evaluation: assess whether temporary DFO cessation and prompt empirical antibiotics reduce septicemia mortality in iron-overloaded patients presenting with fever.
6. Integrated One-Health surveillance: expand PFGE/WGS matching of food, livestock, wildlife, and human isolates to map transmission chains and identify high-risk food vehicles for targeted prevention.